CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignanciesGlobeNewsWire • 11/22/21
CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 DiabetesGlobeNewsWire • 11/16/21
Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR TherapeuticsThe Motley Fool • 11/04/21
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial ResultsGlobeNewsWire • 11/03/21
Earnings Preview: CRISPR Therapeutics AG (CRSP) Q3 Earnings Expected to DeclineZacks Investment Research • 10/20/21
Tuesday Afternoon Analyst Upgrades and Downgrades: CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and More24/7 Wall Street • 10/19/21
3 Beaten-Down Stocks Cathie Wood Is Buying That Wall Street Thinks Will SkyrocketThe Motley Fool • 10/19/21